BioCardia presents trial design on Oct 7, 2026
- Presented CardiAMP HF II Trial design at HFSA meeting
- FDA approved category B designation for CardiAMP cell therapy
- HFSA meeting in Phoenix, AZ from Oct 9-12, 2026
Every EDGAR filing for BioCardia, Inc. (BCDA), newest first, with AI summaries and stories.
Next: earnings expected ~Nov 13 · 10-Q expected ~Nov 13 (deadline Nov 16)
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
Peter Altman, insider filing for BCDA
Peter Altman, reporting
Peter Altman, insider filing for BCDA
Peter Altman, reporting
Peter Altman, insider filing for BCDA
Peter Altman, reporting
Peter Altman, insider filing for BCDA
Peter Altman, reporting
Peter Altman, insider filing for BCDA
Peter Altman, reporting
Peter Altman, insider filing for BCDA
Peter Altman, reporting
Peter Altman, insider filing for BCDA
Peter Altman, reporting
Peter Altman, insider filing for BCDA
Peter Altman, reporting
Peter Altman, insider filing for BCDA
Peter Altman, reporting
Peter Altman, insider filing for BCDA
Peter Altman, reporting
Marvin Slosman, insider filing for BCDA
Marvin Slosman, reporting
Peter Altman, insider filing for BCDA
Peter Altman, reporting
Simon H Stertzer, insider filing for BCDA
Simon H Stertzer, reporting
Peter Altman, insider filing for BCDA
Peter Altman, reporting
Peter Altman, insider filing for BCDA
Peter Altman, reporting
Peter Altman, insider filing for BCDA
Peter Altman, reporting
Peter Altman, insider filing for BCDA
Peter Altman, reporting
Peter Altman, insider filing for BCDA
Peter Altman, reporting
Peter Altman, insider filing for BCDA
Peter Altman, reporting
Peter Altman, insider filing for BCDA
Peter Altman, reporting